The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis

Purpose To investigate the effect of 18 months' parathyroid hormone 1-84 (PTH 1-84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis. Methods Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 +/- 8.1 years old) and 23 healthy controls (mean age 68.9 +/- 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1-84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study. Results At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 +/- 259.7 vs. 260.3 +/- 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 +/- 1.7 vs. 5.7 +/- 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1-84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1-84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 +/- 1.6 vs. 6.0 +/- 1.5 pg/ml, p = 0.53) and VEGF (260.3 +/- 184.3 vs. 257.4 +/- 107.1 pg/ ml, p = 0.94). Conclusions PTH (1-84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.